

Please amend the application as follows.

In the Claims:

Please cancel claims 236-242, 245-256, 259-267 and 270-274 without prejudice.

Please replace claims 110, 212, 221 and 230 with the following amended claims shown below.

Please add claims 279 and 280.

110. (Once Amended) The method of claim 107 wherein said protein is labeled.

212. (Twice Amended) A method of stimulating lymphocyte proliferation, differentiation or survival comprising administering to an individual, a therapeutically effective amount of a protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of amino acid residues n to 285 of SEQ ID NO:2, where n is an integer in the range of 2-190;

(b) the amino acid sequence of amino acid residues 1 to m of SEQ ID NO:2, where m is an integer in the range of 274-284; and

(c) the amino acid sequence of amino acid residues n to m of SEQ ID NO:2, where n is an integer in the range of 2-190 and m is an integer in the range of 274-284;

wherein the polypeptide having said amino acid sequence modulates lymphocyte proliferation, differentiation, or survival.

221. (Twice Amended) A method of stimulating lymphocyte proliferation, differentiation or survival comprising administering to an individual, a therapeutically effective amount of a protein comprising a first amino acid sequence that is 95% or more identical to a second amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of amino acid residues n to 285 of SEQ ID NO:2, where n is an integer in the range of 2-190;

(b) the amino acid sequence of amino acid residues 1 to m of SEQ ID NO:2, where m is an integer in the range of 274-284; and

(c) the amino acid sequence of amino acid residues n to m of SEQ ID NO:2, where n is an integer in the range of 2-190 and m is an integer in the range of 274-284;

wherein the polypeptide having said first amino acid sequence modulates lymphocyte proliferation, differentiation, or survival.

230. (Twice Amended) A method of stimulating lymphocyte proliferation, differentiation or survival comprising administering to an individual, a therapeutically effective amount of a protein consisting of an amino acid sequence of amino acid residues 134-285 of SEQ ID NO:2.

279. (New) The method of claim 107 wherein the immunodeficiency is common variable immunodeficiency (CVID).

280. (New) The method of claim 107 wherein the immunodeficiency is Selective IgA deficiency.